Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8708311 | 0.86 | EPHX2 (0.32) | EPHX2HSD17B10 | |
| Succinic Acid SCHEMBL2849113 | 0.77 | USP5 (0.33) | ALDH1A1 | |
| SCHEMBL4824901 | 0.76 | PRMT3 (0.36) | SIGMAR1ALOX15 | |
| SCHEMBL4630963 | 0.75 | ADRA1D (0.32) | SIGMAR1 | |
| SCHEMBL589584 | 0.73 | HTR1A (0.42) | — | |
| Acetic Acid SCHEMBL1666951 | 0.73 | CHRNB2 (0.30) | — | |
| SCHEMBL1898647 | 0.73 | — | — | |
| SCHEMBL28166840 | 0.73 | PDE4B (0.32) | — | |
| SCHEMBL28056726 | 0.70 | NPC1 (0.41) | EPHX2LMNAKMT2A | |
| SCHEMBL3168555 | 0.69 | QDPR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245283-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2027085-A1 | PROSTAGLANDIN EP4 AGONISTS | Allergan, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007115001-A1 | PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232660-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232660-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | TLR9 1189/4885TLR8 622/4885TLR7 758/4885 |
| US-20130245283-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | TLR9 1189/4885TLR8 622/4885TLR7 758/4885 |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | TLR9 1189/4885TLR8 622/4885TLR7 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.